Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
Data from oral presentation adds to growing body of evidence supporting the profile of PRX012, which is designed to target all aggregated forms of amyloid beta with high binding... | March 31, 2023
Vastra Gotalands Lan Wagner Zago Prothena Corporation International Conference On Alzheimer Exchange Commission Forum Discussions
Source: marketscreener.com